Stockhead host Peter Strachan discusses Artrya’s Salix technology and how through the use of big data and AI it can accurately detect markers and indicators of early heart disease.
Populating the expert panel for this discussion is John Barrington, managing director and co-founder at Artrya (ASX:AYA).
Artrya is an AI healthcare company using non-invasive diagnostic support solution Salix, to detect coronary artery disease.
The recently listed company has begun trials in the US of its Salix technology at the Hunstville Heart centre in Alabama.
The group discuss a range of topics including; how Artrya’s Salix technology identifies heart disease indicators, the high accuracy of the AI system, commercialisation and addressable market, trials in association with Envision and the Huntsville Heart Centre, regulatory approvals and more.